Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atea Pharmaceuticals (AVIR)
NASDAQ:AVIR
RESEARCH TOOLSreports
Holding AVIR?
Track your performance easily
AVIR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.75 - $4.60
Previous Close$3.19
Volume1.24M
Average Volume (3M)264.73K
Market Cap
$269.44M
Enterprise Value-$211.54M
Total Cash (Recent Filing)$482.81M
Total Debt (Recent Filing)$1.83M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Mar 04, 2025EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.07
Shares Outstanding84,463,059
10 Day Avg. Volume726,222
30 Day Avg. Volume264,731
Standard Deviation0.22
R-Squared0.00173
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.59
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.54
Forecast
1Y Price Target
$6.20Price Target Upside94.36% Upside
Rating ConsensusHold
Number of Analyst Covering1
Atea Pharmaceuticals News
PremiumCompany Announcements
Atea Pharmaceuticals Advances in HCV Treatment Development
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe combination of bemnifosbuvir and ruzasvir met its primary endpoints of safety and sustained virologic response at 12 weeks post-treatment in subjects with chronic hepatitis C infection.
High Efficacy RateBEM+RZR demonstrated a 98% sustained virologic response rate in the per-protocol treatment adherent patient population after 8 weeks of treatment.
Regulatory AdvancementManagement plans to hold an end-of-Phase 2 meeting with the FDA and initiate the Phase 3 program shortly thereafter, with plans to run two global Phase 3 trials.
Bears Say
Clinical TrialsAtea announces bemnifosbuvir (oral) did not meet the primary endpoint in high-risk patients with mild to moderate COVID.
Impact Of VariantsMgt. notes that currently circulating variants caused milder disease, which resulted in fewer hospitalizations and deaths.
Treatment ChallengesPatient adherence and cirrhotic status remain challenges in the treatment of HCV.
---
Ownership Overview
11.47% Insiders
14.44% Mutual Funds
27.46% Other Institutional Investors
35.11% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AVIR FAQ
What was Atea Pharmaceuticals’s price range in the past 12 months?
Atea Pharmaceuticals lowest stock price was $2.75 and its highest was $4.60 in the past 12 months.
What is Atea Pharmaceuticals’s market cap?
Currently, no data Available
When is Atea Pharmaceuticals’s upcoming earnings report date?
Atea Pharmaceuticals’s upcoming earnings report date is Mar 04, 2025 which is in 72 days.
How were Atea Pharmaceuticals’s earnings last quarter?
Atea Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.427 by $0.057.
Is Atea Pharmaceuticals overvalued?
According to Wall Street analysts Atea Pharmaceuticals’s price is currently Undervalued.
Does Atea Pharmaceuticals pay dividends?
Atea Pharmaceuticals does not currently pay dividends.
What is Atea Pharmaceuticals’s EPS estimate?
Atea Pharmaceuticals’s EPS estimate is -$0.29.
How many shares outstanding does Atea Pharmaceuticals have?
Atea Pharmaceuticals has 84,463,060 shares outstanding.
What happened to Atea Pharmaceuticals’s price movement after its last earnings report?
Atea Pharmaceuticals reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.427. Following the earnings report the stock price went up 1.744%.
Which hedge fund is a major shareholder of Atea Pharmaceuticals?
Among the largest hedge funds holding Atea Pharmaceuticals’s share is Woodline Partners LP. It holds Atea Pharmaceuticals’s shares valued at 346K.
---
Atea Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.20 (94.36% Upside)
$6.20 (94.36% Upside)
Hedge Fund Trend
Increased
By 103.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.62%
12-Months-Change
Fundamentals
Return on Equity
-33.45%
Trailing 12-Months
Asset Growth
-19.26%
Trailing 12-Months
Company Description
Atea Pharmaceuticals
Atea Pharmaceuticals Inc is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science.
---
AVIR Company Deck
---
AVIR Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Atea Pharmaceuticals, with a strong financial position and promising progress in their HCV program. However, the challenges with the SUNRISE-3 trial and patient adherence issues present areas of concern.Read More>---
AVIR Stock 12 Month Forecast
Average Price Target
$6.20
▲(94.36% Upside)
Technical Analysis
---